BICO Group AB (publ) (BICO) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and welcome to BICO Group's Quarter one twenty twenty six Earnings Call. I'm Maria Fors, President and CEO, and I will, together with BICO's CFO, Eva Linzetti, present this interim report. Here is today's agenda. I will open today's session by summarizing quarter one twenty twenty six and also describe how BICO serves the world's leading pharma and biotech companies with solutions that transform how labs operate, innovate, and solve our customers' challenges. Following that, Eva will present the group's financial performance. I will then comment on our r and d pipeline with our ongoing product development efforts. Additionally, I will highlight some recent and upcoming product launches. The session will conclude by highlighting our focus for 2026 before we open up for Q and A. A strong start to the year with 11% organic growth, navigating in a dynamic market still affected by geopolitical uncertainty and a weak academic funding in The U. S. Due to continued currency headwinds, our total reported growth was negative 1.4%. All numbers presented are in 1,000,000 unless otherwise stated. EBITDA was negative SEK 42,000,000 with adjusted EBITDA of negative SEK 11,000,000. And the difference is mainly relates to a restructuring cost of SEK 52,000,000, of which SEK 30,000,000 affected EBITDA. Cash flow from operating activities totaled SEK 47,000,000. BICO successfully issued senior secured bonds of DKK 40,000,000 and the new capital puts us in a position to support further growth and capture market recovery, while navigating ongoing macroeconomic uncertainty. A property in Oulu, Finland carved out from the divestment of Denolis was also divested for a total of EUR 3,500,000. We settled our convertible bonds originally issued in 2021 with a total outstanding amount of...